Topline data were announced from a phase 3 trial evaluating secukinumab in patients with polymyalgia rheumatica.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback